Jaykumar Thumar, MBBS, MD
Adjunct Assistant ProfessorDownloadHi-Res Photo
About
Titles
Adjunct Assistant Professor
Biography
Dr Thumar completed his residency (Internal Medicine) from Civil Hospital, Ahmedabad, India. During his medical training at Gujarat Cancer Research Institute he developed major interest in medical oncology and basic science research. He served as post doctoral research fellow at Center for Vascular Biology, University of Connecticut. He completed his additional internship and residency training in internal medicine at University of Connecticut, Farmington, CT. He served as Chief Medical Resident at John Dempsey Hospital, Farmington, CT. He then served as a Fellow in Hematology and Oncology at Yale Cancer Center, New Haven, CT.
Appointments
Medical Oncology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
- Internal Medicine
- Medical Oncology
- Subset Medical Oncology Faculty
- Yale Cancer Center
Education & Training
- MD
- Yale University, Medical Hematology Oncology (2012)
- Chief Medical Resident
- University of Connecticut (2009)
- MD
- University of Connecticut, Internal Medicine (2008)
- MBBS
- B.J. Medical College (2000)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Jaykumar Thumar's published research.
Daniel Zelterman, PhD
Jeremy Kortmansky, MD
Jingjing Jiao
Kevin Billingsley, MD, MBA, FACS
Kimberly L. Johung, MD, PhD
Luisa Escobar-Hoyos, MSc, PhD
Publications
2024
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.
Shroff R, King G, Colby S, Scott A, Borad M, Goff L, Matin K, Mahipal A, Kalyan A, Javle M, El Dika I, Tan B, Cheema P, Patel A, Iyer R, Kelley R, Thumar J, El-Khoueiry A, Guthrie K, Chiorean E, Hochster H, Philip P. SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. Journal Of Clinical Oncology 2024, jco2401383. PMID: 39671534, DOI: 10.1200/jco-24-01383.Peer-Reviewed Original ResearchConceptsProgression-free survivalBiliary tract cancerAdvanced biliary tract cancerOverall survivalGallbladder carcinomaExtrahepatic cholangiocarcinomaIntrahepatic cholangiocarcinomaHazard ratioNab-paclitaxelMedian progression-free survivalMetastatic biliary tract cancerProgression-free survival benefitPhase III randomized trialGemcitabine-cisplatin regimenTrial of gemcitabineLocally advanced diseaseExploratory subset analysisDiagnosing BTCEvaluated gemcitabineMedian OSMetastatic diseaseAdvanced diseaseNo significant differenceSubset analysisGemcitabinePerioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchConceptsProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOX
Clinical Trials
Current Trials
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
HIC ID2000030190RoleSub InvestigatorPrimary Completion Date06/02/2026Recruiting ParticipantsNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
HIC ID2000028918RoleSub InvestigatorPrimary Completion Date01/01/2025Recruiting ParticipantsGBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
HIC ID2000026339RoleSub InvestigatorPrimary Completion Date06/30/2026Recruiting ParticipantsA Phase II Evaluation of Afatinib
HIC ID1503015437RoleSub InvestigatorPrimary Completion Date07/31/2025Recruiting ParticipantsGenderFemaleAgeUp to 18 years